DOCSLIB.ORG

Validation of Cytochrome P450 2C8 Inhibition Assay

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Validation of Cytochrome P450 2C8 Inhibition Assay MQP-BIO-DSA-0262 Validation of Cytochrome P450 2C8 Inhibition Assay A Major Qualifying Project Report Submitted to the Faculty of the W ORCESTER POLYTECHNIC INSTITUTE In partial fulfillment of the requirements for the Degree of Bachelor of Science in Biology and Biotechnology By ______________________ Matthew Schulze April 24, 2008 APPROVED: _______________________ _______________________ Adrian Sheldon, Ph.D. David Adams, Ph.D. Associate Director (Invitro ADMET) Biology and Biotechnology Charles River Laboratories Preclinical Services W PI Project Advisor Major Advisor ABSTRACT One of the most important pharmaceutical properties of a drug candidate to be determined during any pre-clinical discovery is the effect of the specific test compound on the activity of Cytochrome P450, a key enzyme involved in drug metabolism. The purpose of this project was to validate a Cytochrome P450 2C8 (CYP2C8) enzyme inhibition assay in development at Charles River Labs (W orcester). The assay quantitates the in vitro inhibition of CYP2C8 by a test compound as measured by the amount of specific metabolite generated by CYP2C8-specific drug substrates Amodiaquine (AMOD) and Paclitaxel (PACL). The data presented here validate the assay. TABLE OF CONTENTS Abstract.......................................................................................................................................- 2 - Table of Figures ..........................................................................................................................- 4 - Acknowledgements.....................................................................................................................- 6 - Background.................................................................................................................................- 7 - Drug Metabolism & Biotransformation ..................................................................................- 7 - Cytochrome P450..................................................................................................................- 11 - History...............................................................................................................................- 12 - Biochemistry......................................................................................................................- 14 - Cytochrome P450 2C8 ..........................................................................................................- 19 - Structure of CYP2C8.........................................................................................................- 20 - Metabolism of CYP2C8 ....................................................................................................- 21 - Project Purpose .........................................................................................................................- 24 - Methods.....................................................................................................................................- 25 - Enzyme Titration...................................................................................................................- 26 - Substrate Titration.................................................................................................................- 27 - CYP2C8 Inhibition................................................................................................................- 27 - Results.......................................................................................................................................- 28 - Discussion.................................................................................................................................- 33 - Bibliography.............................................................................................................................- 35 - TABLE OF FIGURES Figure 1: Definitions of Specificity. (Monosson, 2008).............................................................- 1 - Figure 2: Visual Description of Oxidation and Reduction (Phase I) reactions. ("Mnemonic: Oxidation and Reduction.“, 13 Feb 2008) ..................................................................................- 1 - Figure 3: Model of the conserved tertiary structure of CYP monooxygenase. The heme is orange, substrate recognition site is red, and the heme coordinating I and L helices are green. (Urlacher & Eiben, 2006)............................................................................................................................- 1 - Figure 4: —Carbon monoxide-difference spectra for NADH-reduced (- - -) and Na2S2O4-reduced (–) rat liver microsomes.“ (Sato & Omura, 1978) ....................................................................- 1 - Figure 5: Drug discovery and development process. (—KinomeScan“, 13 Feb 2008)................- 1 - Figure 7: epoxidation of styrene to styrene oxide. (Urlacher & Eiben, 2006)............................- 1 - Figure 8: Hydroxylation of fatty acids to hydroxyl-fatty acids. (Urlacher & Eiben, 2006) .......- 1 - Figure 6: Hydroxylation of an aromatic compound naphthalene to 2-naphol/1-naphol. (Urlacher & Eiben, 2006)............................................................................................................................- 1 - Figure 9: The fold and active site for CYP. Black displays the substrate recognition sites (SRS). (Denisov et al., 2005)..................................................................................................................- 1 - Figure 10: Predicted secondary structure of Cytochrome P450 2C8 Dimer Enzyme. Light blue=turns; Pink=coils; Green=helices; Purple=strands; Magenta(center)=two palmitic acid molecules; Magenta(top and bottom)= hemes (Produced in MBT Protein W orkshop, Jan 2008)..- 1 - Figure 12: Metabolism of PACK to 6M-hydroxypaclitaxel. (Separations of Paclitaxel and Its Metabolite 6a-Hydroxypaclitaxel.).............................................................................................- 1 - Figure 11: Metabolism of AMOD to DEAQ. (Li et al., 2002) ...................................................- 1 - Figure 13: IC50 plots of amodiaquine inhibition in CYP2C8 by montelukast (•), candesartan cilexetil (), zafirlukast (), quercetin (), and gemfibrozil (). (W alsky et al., 2005) ........- 1 - Figure 15: IS Peak Area vs. Index of DEAQ using DESA-d3 as an IS......................................- 1 - Figure 14: IS Peak Area vs. Index of DESA-d3 using RSRP as an IS.......................................- 1 - Figure 16: Graphs of Average Area Ratio (Analyte Peak Area / IS Peak Area) vs. Enzyme Concentration for T=30 on the left and T=0 on the right. ..........................................................- 1 - Figure 17: Graph of Average Area Ratio (Analyte Peak / IS Peak) vs. substrate concentration (µM)............................................................................................................................................- 1 - Figure 18: Graph of Average Area Ratio (Analyte Peak / IS Peak) vs. substrate concentration (µM)............................................................................................................................................- 1 - Figure 20: IC50 of QRCT is 4.2 µM............................................................................................- 1 - Figure 19: IC50 of MONT is 0.3 µM...........................................................................................- 1 - ACKNOW LEDGEM ENTS First I would like to thank Adrian Sheldon for letting me use the Invitro ADMET lab at Charles River Laboratories. I would also like to thank Sarah Mitchell, Patty W alton, Susan Dearborn, and Ali Maarouf for showing me procedures that I was initially unfamiliar with, and getting me accustomed to the lab, for helping with my report writing, and most importantly for their guidance and direction. Thank you also to the Charles River Laboratories Preclinical Facilities in Shrewsbury and W orcester for providing the necessary methods, materials and laboratory space respectfully. Finally, I would like to thank Professor David Adams for his assistance in setting this project up, his help writing the report, and his continued support. BACKGROUND Drug Metabolism & Biotransformation A drug is defined as a substance taken for either medicinal or recreational use. After digestion, the substance circulates, enters the circulatory system, and begins to undergo metabolism or biotransformation. This process can be best described as —breaking down“ the drug whatever it may be, but it always involves the chemical modification or degradation of the drug. These changes can occur in any tissue, but most of them occur in hepatocytes. The liver produces numerous enzymes that alter drugs and toxins in order to clear them from the circulatory systems and excrete them in the bile. These enzymatic systems use a variety of reactions to metabolize drugs, such as oxidation, reduction, and hydrolysis. As these changes occur new metabolites are produced that may or may not remain active in vivo. However, the majority of these metabolites will enter the kidney where they can be processed and expelled in the urine, solid waste, or perspiration (—Liver“, 2005). Biotransformation is vital to the survival of an organism because it allows for necessary nutrients to be absorbed as they are transformed, metabolize drugs into metabolites that may be the therapeutic, and of course are a mechanism of defense against
Load more

Recommended publications
  • Next-Generation Sequencing of Representational Difference Analysis
    Planta DOI 10.1007/s00425-017-2657-0 ORIGINAL ARTICLE Next-generation sequencing of representational difference analysis products for identification of genes involved in diosgenin biosynthesis in fenugreek (Trigonella foenum-graecum) 1 1 1 1 Joanna Ciura • Magdalena Szeliga • Michalina Grzesik • Mirosław Tyrka Received: 19 August 2016 / Accepted: 30 January 2017 Ó The Author(s) 2017. This article is published with open access at Springerlink.com Abstract Within the transcripts related to sterol and steroidal Main conclusion Representational difference analysis saponin biosynthesis, we discovered novel candidate of cDNA was performed and differential products were genes of diosgenin biosynthesis and validated their sequenced and annotated. Candidate genes involved in expression using quantitative RT-PCR analysis. Based on biosynthesis of diosgenin in fenugreek were identified. these findings, we supported the idea that diosgenin is Detailed mechanism of diosgenin synthesis was biosynthesized from cycloartenol via cholesterol. This is proposed. the first report on the next-generation sequencing of cDNA-RDA products. Analysis of the transcriptomes Fenugreek (Trigonella foenum-graecum L.) is a valuable enriched in low copy sequences contributed substantially medicinal and crop plant. It belongs to Fabaceae family to our understanding of the biochemical pathways of and has a unique potential to synthesize valuable steroidal steroid synthesis in fenugreek. saponins, e.g., diosgenin. Elicitation (methyl jasmonate) and precursor feeding (cholesterol and squalene) were Keywords Diosgenin Á Next-generation sequencing Á used to enhance the content of sterols and steroidal Phytosterols Á Representational difference analysis of sapogenins in in vitro grown plants for representational cDNA Á Steroidal saponins Á Transcriptome user-friendly difference analysis of cDNA (cDNA-RDA).
    [Show full text]
  • Relating Metatranscriptomic Profiles to the Micropollutant
    1 Relating Metatranscriptomic Profiles to the 2 Micropollutant Biotransformation Potential of 3 Complex Microbial Communities 4 5 Supporting Information 6 7 Stefan Achermann,1,2 Cresten B. Mansfeldt,1 Marcel Müller,1,3 David R. Johnson,1 Kathrin 8 Fenner*,1,2,4 9 1Eawag, Swiss Federal Institute of Aquatic Science and Technology, 8600 Dübendorf, 10 Switzerland. 2Institute of Biogeochemistry and Pollutant Dynamics, ETH Zürich, 8092 11 Zürich, Switzerland. 3Institute of Atmospheric and Climate Science, ETH Zürich, 8092 12 Zürich, Switzerland. 4Department of Chemistry, University of Zürich, 8057 Zürich, 13 Switzerland. 14 *Corresponding author (email: [email protected] ) 15 S.A and C.B.M contributed equally to this work. 16 17 18 19 20 21 This supporting information (SI) is organized in 4 sections (S1-S4) with a total of 10 pages and 22 comprises 7 figures (Figure S1-S7) and 4 tables (Table S1-S4). 23 24 25 S1 26 S1 Data normalization 27 28 29 30 Figure S1. Relative fractions of gene transcripts originating from eukaryotes and bacteria. 31 32 33 Table S1. Relative standard deviation (RSD) for commonly used reference genes across all 34 samples (n=12). EC number mean fraction bacteria (%) RSD (%) RSD bacteria (%) RSD eukaryotes (%) 2.7.7.6 (RNAP) 80 16 6 nda 5.99.1.2 (DNA topoisomerase) 90 11 9 nda 5.99.1.3 (DNA gyrase) 92 16 10 nda 1.2.1.12 (GAPDH) 37 39 6 32 35 and indicates not determined. 36 37 38 39 S2 40 S2 Nitrile hydration 41 42 43 44 Figure S2: Pearson correlation coefficients r for rate constants of bromoxynil and acetamiprid with 45 gene transcripts of ECs describing nucleophilic reactions of water with nitriles.
    [Show full text]
  • ( 12 ) United States Patent
    US010208322B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,208 , 322 B2 Coelho et al. (45 ) Date of Patent: * Feb . 19, 2019 ( 54 ) IN VIVO AND IN VITRO OLEFIN ( 56 ) References Cited CYCLOPROPANATION CATALYZED BY HEME ENZYMES U . S . PATENT DOCUMENTS 3 , 965 ,204 A 6 / 1976 Lukas et al. (71 ) Applicant: California Institute of Technology , 4 , 243 ,819 A 1 / 1981 Henrick Pasadena , CA (US ) 5 ,296 , 595 A 3 / 1994 Doyle 5 , 703 , 246 A 12 / 1997 Aggarwal et al. 7 , 226 , 768 B2 6 / 2007 Farinas et al. ( 72 ) Inventors : Pedro S . Coelho , Los Angeles, CA 7 , 267 , 949 B2 9 / 2007 Richards et al . (US ) ; Eric M . Brustad , Durham , NC 7 ,625 ,642 B2 12 / 2009 Matsutani et al. (US ) ; Frances H . Arnold , La Canada , 7 ,662 , 969 B2 2 / 2010 Doyle et al. CA (US ) ; Zhan Wang , San Jose , CA 7 ,863 ,030 B2 1 / 2011 Arnold (US ) ; Jared C . Lewis , Chicago , IL 8 ,247 ,430 B2 8 / 2012 Yuan 8 , 993 , 262 B2 * 3 / 2015 Coelho . .. .. .. • * • C12P 7 /62 (US ) 435 / 119 9 ,399 , 762 B26 / 2016 Farwell et al . (73 ) Assignee : California Institute of Technology , 9 , 493 ,799 B2 * 11 /2016 Coelho .. C12P 7162 Pasadena , CA (US ) 2006 / 0030718 AL 2 / 2006 Zhang et al. 2006 / 0111347 A1 5 / 2006 Askew , Jr . et al. 2007 /0276013 AL 11 /2007 Ebbinghaus et al . ( * ) Notice : Subject to any disclaimer , the term of this 2009 /0238790 A2 9 /2009 Sommadosi et al. patent is extended or adjusted under 35 2010 / 0056806 A1 3 / 2010 Warren U .
    [Show full text]
  • Geneid T-Test Q-Val Gene Symbol Gene Title GO Biological Process
    Supplementary Table 2. Genes selected by FADA as the most discriminant between tumoral and normal prostate samples GO Biological Process GO Molecular Function GO Cellular Component GeneID T-test q-val Gene Symbol Gene Title Description Description Description Pathway serine-type endopeptidase inhibitor activity /// endopeptidase inhibitor serpin peptidase inhibitor, clade activity /// serine-type endopeptidase 213572_s_at -6.753 2.213E-05 SERPINB1 B (ovalbumin), member 1 --- inhibitor activity cytoplasm --- ion transport /// cellular defense response /// positive regulation of T-cell, immune regulator 1, cell proliferation /// proton plasma membrane /// integral to ATPase, H+ transporting, transport /// transport /// proton transporter activity /// hydrogen ion plasma membrane /// membrane /// 204158_s_at -5.729 8.585E-05 TCIRG1 lysosomal V0 subunit A3 transport transporter activity integral to membrane --- chemotaxis /// cell adhesion /// homophilic cell adhesion /// nervous system development /// cell differentiation /// positive roundabout, axon guidance regulation of axonogenesis /// receptor activity /// axon guidance integral to plasma membrane /// cell receptor, homolog 1 development /// nervous system receptor activity /// identical protein surface /// membrane /// integral to 213194_at -6.168 4.441E-05 ROBO1 (Drosophila) development binding /// protein binding membrane --- structural molecule activity /// nucleus /// intermediate filament /// protein binding /// microtubule cytoplasmic dynein complex /// 203411_s_at -5.297 1.636E-04
    [Show full text]
  • SUPPLEMENTARY MATERIAL Supplementary Table 1
    Predicting Drug Promiscuity Using Spherical Harmonic Surface The Open Conference Proceedings Journal, 2011, Volume 2 i SUPPLEMENTARY MATERIAL Supplementary Table 1. MDDR Target Annotations Used in the Promiscuity Predictions TARGET_KEY EXTERNAL_ID 1001 prostaglandin-endoperoxide synthase 1002 cyclooxygenase 1 1003 cyclooxygenase 2 1046 ribonucleoside-diphosphate reductase 1112 thymidylate synthase 1209 phosphoribosylglycinamide formyltransferase 1609 purine-nucleoside phosphorylase 1611 uridine phosphorylase 1637 nad adp-ribosyltransferase 1657 transferring alkyl or aryl groups, other than methyl groups 1798 thymidine kinase 1814 protein kinase 1843 1-phosphatidylinositol 4-kinase 1883 protein-tyrosine kinase 1973 nucleotidyltransferase 2018 rna-directed dna polymerase 2121 phospholipase a2 2124 acetylcholinesterase 2282 phosphoric diester hydrolase 2283 phosphodiesterase i 2309 3',5'-cyclic-nucleotide phosphodiesterase 2310 3',5'-cyclic-gmp phosphodiesterase 2316 steryl-sulfatase 2414 alpha-glucosidase 2565 adenosylhomocysteinase 2576 peptidase 25 aldehyde reductase 2613 dipeptidyl-peptidase iv 2619 peptidyl-dipeptidase a 2624 serine-type d-ala-d-ala carboxypeptidase 2659 serine endopeptidase 2663 trypsin 2664 thrombin 2665 coagulation factor xa 2672 coagulation factor viia 2695 tryptase 2742 cathepsin b 2750 cathepsin l 2765 caspase-1 2784 hiv-1 retropepsin 2811 metalloendopeptidase 2822 stromelysin 1 286 xanthine oxidase 2978 beta-lactamase 3014 adenosine deaminase ii The Open Conference Proceedings Journal, 2011, Volume 2 Pérez-Nueno
    [Show full text]
  • Dalmanol Biosyntheses Require Coupling of Two Separate Polyketide Gene Clusters
    Showcasing research progress from Professor Ren Xiang Tan’s As featured in: laboratories at Nanjing University & Nanjing University of Chinese Medicine, Nanjing, China. Dalmanol biosyntheses require coupling of two separate polyketide gene clusters The biosynthesis of immunosuppressants (dalmanol A and acetodalmanol A) is characterized by the coupling of two separate (naphthalene- and chromane-encoding) gene clusters under the catalysis of unspecifi c enzyme(s) that may distribute widely in the fungal kingdom. The fi nding highlights an access to the inter-cluster orchestration derived chemodiversity of microbial secondary metabolites that remain to be a reliable source of leading compounds triggering the development of See Ren Xiang Tan et al., new medicines, agrochemicals, and other tool molecules. Chem. Sci., 2019, 10, 73. rsc.li/chemical-science Registered charity number: 207890 Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue Dalmanol biosyntheses require coupling of two separate polyketide gene clusters† Cite this: Chem. Sci.,2019,10,73 a a bc a a All publication charges for this article Zhen Zhen Zhou, Hong Jie Zhu, Li Ping Lin, Xuan Zhang, Hui Ming Ge, have been paid for by the Royal Society Rui Hua Jiaoa and Ren Xiang Tan *ab of Chemistry Polyketide–polyketide hybrids are unique natural products with promising bioactivity, but the hybridization processes remain poorly understood. Herein, we present that the biosynthetic pathways of two immunosuppressants, dalmanol A and acetodalmanol A, result from an unspecific monooxygenase triggered hybridization of two distinct polyketide (naphthalene and chromane) biosynthetic gene clusters. The orchestration of the functional dimorphism of the polyketide synthase (ChrA) ketoreductase (KR) domain (shortened as ChrA KR) with that of the KR partner (ChrB) in the bioassembly line increases the polyketide diversity and allows the fungal generation of plant chromanes (e.g., noreugenin) and phloroglucinols (e.g., 2,4,6-trihydroxyacetophenone).
    [Show full text]
  • A Network-Based Analysis of Traditional Chinese Medicine Cold and Hot Patterns in Rheumatoid Arthritis
    A Network-Based Analysis of Traditional Chinese Medicine Cold and Hot Patterns in Rheumatoid Arthritis By: Gao Chen, Cheng Lu, Qinglin Zha, Cheng Xiao, Shijie Xu, Dahong Ju, Youwen Zhou, Wei Jia, and Aiping Lu Chen, G., Lu, Cheng, Zha, Q.L., Xiao, C., Xu, S.J., Ju, D.H., Zhou, Y.W., Jia, W., Lu, A.P. (2012). A network-based analysis of traditional Chinese medicine cold and hot patterns in rheumatoid arthritis, Complementary Therapies in Medicine, 20(1-2), 23-30. ***Note: This version of the document is not the copy of record. Made available courtesy of Elsevier. Link to Article: http://www.sciencedirect.com/science/article/pii/S0965229911001579 Abstract: Objective- Rheumatoid arthritis (RA) is a heterogeneous disease, and traditional Chinese medicine (TCM) can be used to classify RA into different patterns such as cold and hot based on its clinical manifestations. The aim of this study was to investigate potential network-based biomarkers for RA with either a cold or a hot pattern. Method- Microarray technology was used to reveal gene expression profiles in CD4+ T cells from 21 RA patients with cold pattern and 12 with hot pattern. A T-test was used to identify significant differences in gene expression among RA patients with either cold or hot pattern. Cytoscape software was used to search the existing literature and databases for protein–protein interaction information for genes of interest that were identified from this analysis. The IPCA algorithm was used to detect highly connected regions for inferring significant complexes or pathways in this protein–protein interaction network.
    [Show full text]
  • Abuse-Deterrent Pharmaceutical Compositions
    (19) TZZ¥ _Z¥Z_T (11) EP 3 210 630 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 30.08.2017 Bulletin 2017/35 A61K 47/36 (2006.01) A61K 9/14 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) (2006.01) (2006.01) (21) Application number: 16157803.4 A61K 31/455 A61K 31/485 (22) Date of filing: 29.02.2016 (84) Designated Contracting States: (71) Applicant: G.L. Pharma GmbH AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 8502 Lannach (AT) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (72) Inventor: The designation of the inventor has not Designated Extension States: yet been filed BA ME Designated Validation States: (74) Representative: Sonn & Partner Patentanwälte MA MD Riemergasse 14 1010 Wien (AT) (54) ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS (57) Disclosed are pharmaceutical compositions comprising oxycodone and an oxycodone-processing enzyme, wherein oxycodone is contained in the pharmaceutical composition in a storage stable, enzyme-reactive state and under conditions wherein no enzymatic activity acts on oxycodone. EP 3 210 630 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 210 630 A1 Description [0001] The present application relates to abuse-deterrent pharmaceutical compositions comprising oxycodone. [0002] Prescription opioid products are an important component of modern pain management. However, abuse and 5 misuse of these products have created a serious and growing public health problem. One potentially important step towards the goal of creating safer opioid analgesics has been the development of opioids that are formulated to deter abuse.
    [Show full text]
  • Tumor-Normal (Log2) Gene Title 1559057 at -1.71 Chrx Orf45 205833 S at -1.73 Prostate Androgen-Regulated Transcript 1 223150 S A
    Tumor-Normal (log2) Gene Title 1559057_at -1.71 ChrX orf45 205833_s_at -1.73 Prostate androgen-regulated transcript 1 223150_s_at 0.98 protein tyrosine phosphatase, non-receptor type 23 204856_at 0.91 UDP-GlcNAc:betaGal beta-1,3-NAcGlctransferase 3 232932_at -1.44 Hypothetical protein LOC645030 237669_at -1.13 Protein tyrosine phosphatase domain containing 1 235041_at 0.81 golgi SNAP receptor complex member 2 243580_at 1.16 Guanine nucleotide binding protein (G protein), alpha 14 234354_x_at -1.28 erb-b2 (Her2) erythroblastic leukemia viral oncogene homolog 2 217228_s_at 1.07 ankyrin repeat and SOCS box-containing 4 232690_at -1.53 Mannosyl (alpha-1,3-)-glycoprotein 244371_at 1.36 Hypothetical protein MGC16169 204924_at 1.15 toll-like receptor 2 1559382_at 0.89 chr19 orf 42 239965_at 0.86 hypothetical protein LOC151878 202409_at 4.11 chr11 orf 43 235630_at 0.66 Transcribed locus 236879_at 0.79 Ubiquitin-activating enzyme E1-like 2 221237_s_at -1.59 oxysterol binding protein 2 230443_at -1.30 NHP2 non-histone chromosome protein 2-like 1 208250_s_at -0.70 deleted in malignant brain tumors 1 235814_at -1.18 Transcribed locus 231544_s_at -1.76 CDNA: FLJ21837 fis, clone HEP01664 243767_at 0.83 Transcribed locus 241865_at 0.72 G protein, beta polypeptide 1 237350_at -1.54 similar to CDNA sequence BC021608 227670_at -1.12 zinc finger protein 75a 217100_s_at 0.75 UBX domain containing 7 240422_at -1.19 Flavin containing monooxygenase 5 230000_at 0.87 chr17 orf 27 230599_at 0.80 Ring finger protein 19 204433_s_at -1.18 spermatogenesis associated
    [Show full text]
  • Supplementary File 1
    Electronic Supplementary Material (ESI) for Food & Function. This journal is © The Royal Society of Chemistry 2021 Supplementary File 1 Table S1 Targets corresponding to EACC components No. Gene ID Gene Symbol Description ATP-dependent translocase ABCB1 (ATP-binding cassette sub-family B member 1A) (MDR1A) (Multidrug resistance 1 18671 Abcb1a protein 1A) (EC 7.6.2.2) (Multidrug resistance protein 3) (P-glycoprotein 3) (Phospholipid transporter ABCB1) (EC 7.6.2.1) ATP-dependent translocase ABCB1 (ATP-binding cassette sub-family B member 1B) (Multidrug resistance protein 2 18669 Abcb1b 1B) (EC 7.6.2.2) (P-glycoprotein 1) (Phospholipid transporter ABCB1) (EC 7.6.2.1) (CD antigen CD243) Multidrug resistance-associated protein 1 (EC 7.6.2.2) (ATP-binding cassette sub-family C member 1) 3 17250 Abcc1 (Glutathione-S-conjugate-translocating ATPase ABCC1) (EC 7.6.2.3) (Leukotriene C(4) transporter) (LTC4 transporter) Broad substrate specificity ATP-binding cassette transporter ABCG2 (EC 7.6.2.2) (ATP-binding cassette 4 26357 Abcg2 sub-family G member 2) (Breast cancer resistance protein 1 homolog) (Urate exporter) (CD antigen CD338) 5 27405 Abcg3 ATP-binding cassette sub-family G member 3 Monoacylglycerol lipase ABHD6 (EC 3.1.1.23) (2- 6 66082 Abhd6 arachidonoylglycerol hydrolase) (Abhydrolase domain- containing protein 6) Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson 7 11350 Abl1 murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150) Acetyl-CoA carboxylase 1 (ACC1) (EC 6.4.1.2) (ACC-alpha)
    [Show full text]
  • Alterations in Progesterone Catabolic Enzymes by Insulin
    Graduate Theses, Dissertations, and Problem Reports 2007 Alterations in progesterone catabolic enzymes by insulin Caleb Owens Lemley West Virginia University Follow this and additional works at: https://researchrepository.wvu.edu/etd Recommended Citation Lemley, Caleb Owens, "Alterations in progesterone catabolic enzymes by insulin" (2007). Graduate Theses, Dissertations, and Problem Reports. 2536. https://researchrepository.wvu.edu/etd/2536 This Thesis is protected by copyright and/or related rights. It has been brought to you by the The Research Repository @ WVU with permission from the rights-holder(s). You are free to use this Thesis in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Thesis has been accepted for inclusion in WVU Graduate Theses, Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU. For more information, please contact [email protected]. Alterations in Progesterone Catabolic Enzymes by Insulin Caleb Owens Lemley Thesis submitted to the Davis College of Agriculture, Forestry and Consumer Sciences at West Virginia University in partial fulfillment of the requirements for the degree of Master of Science in Reproductive Physiology Matthew E. Wilson, Ph.D., Chair Kenneth P. Blemings, Ph.D. K. Marie Krause, Ph.D. Division of Animal and Nutritional Sciences Morgantown, WV 2007 Keywords: Progesterone Catabolism, Insulin, Glucagon, Cytochrome P450 ABSTRACT Alterations in Progesterone Catabolic Enzymes by Insulin Caleb Owens Lemley The current experiments were conducted to determine if insulin could alter the progesterone catabolic enzymes, cytochrome P450 2C and 3A in vitro, utilizing a mouse hepatocyte cell-line, or in vivo, utilizing the ovariectomized ewe as a model.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,993,262 B2 Coelho Et Al
    USOO8993262B2 (12) United States Patent (10) Patent No.: US 8,993,262 B2 Coelho et al. (45) Date of Patent: Mar. 31, 2015 (54) IN VIVO AND IN VITRO OLEFIN 2006/0030718 A1* 2/2006 Zhang et al. .................. 548,954 CYCLOPROPANATION CATALYZED BY 2006/01 11347 A1 5/2006 Askew, Jr. et al. 2007/0276013 A1 1 1/2007 Ebbinghaus et al. HEMIE ENZYMES 2009/0238790 A2 9/2009 Sommadossi et al. 2010.00568.06 A1 3/2010 Warren (71) Applicant: California Institute of Technology, 2010/0168463 A1 7, 2010 Hirata et al. Pasadena, CA (US) 2010/024010.6 A1 9/2010 Wong et al. 2011 0196086 A1 8, 2011 Matsushita et al. (72) Inventors: Pedro S. Coelho, Los Angeles, CA (US); 2012/0237591 A1 9, 2012 Cullis et al. Eric M. Brustad, Durham, NC (US); Frances H. Arnold, La Canada, CA FOREIGN PATENT DOCUMENTS (US); Zhan Wang. San Jose, CA (US); EP O 200 638 B1 4, 1986 Jared C. Lewis, Chicago, IL (US) WO 2007 144599 A2 12/2007 WO 2011, 1595.50 A3 12/2011 (73) Assignee: California Institute of Technology, Pasadena, CA (US) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Adams, P.D. et al., “PHENIX: a comprehensive Python-based system patent is extended or adjusted under 35 for macromolecular structure solution.” Acta Crystallogr., Sect. D, U.S.C. 154(b) by 0 days. R.JKumar, F.K.R. et R.O.al., 1soprenoid painwayNavonimation optimization Ioror taxoto (21) Appl. No.: 14/185.861 precursor overproduction in Escherichia coli,” Science, 2010, y x- - - 9 330:70-74.
    [Show full text]